<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: S100A12 is a pro-inflammatory protein that is secreted by granulocytes </plain></SENT>
<SENT sid="1" pm="."><plain>S100A12 serum levels increase during <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> (IBD) </plain></SENT>
<SENT sid="2" pm="."><plain>We performed the first study analysing faecal S100A12 in adults with signs of <z:mp ids='MP_0001858'>intestinal inflammation</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Faecal S100A12 was determined by ELISA in faecal specimens of 171 consecutive patients and 24 healthy controls </plain></SENT>
<SENT sid="4" pm="."><plain>Patients either suffered from <z:e sem="disease" ids="C0277525" disease_type="Disease or Syndrome" abbrv="">infectious gastroenteritis</z:e> confirmed by stool analysis (65 <z:mp ids='MP_0001794'>bacterial</z:mp>, 23 <z:mp ids='MP_0001799'>viral</z:mp>) or underwent endoscopic and histological investigation (32 with <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo>, 27 with <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo>, and 24 with <z:e sem="disease" ids="C0022104" disease_type="Disease or Syndrome" abbrv="IBS">irritable bowel syndrome</z:e>; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IBS</z:e>) </plain></SENT>
<SENT sid="5" pm="."><plain>Intestinal S100A12 expression was analysed in biopsies obtained from <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="6" pm="."><plain>Faecal calprotectin was used as an additional non-invasive surrogate marker </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Faecal S100A12 was significantly higher in patients with active IBD (2.45 +/- 1.15 mg/kg) compared with healthy controls (0.006 +/- 0.03 mg/kg; p&lt;0.001) or patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IBS</z:e> (0.05 +/- 0.11 mg/kg; p&lt;0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>Faecal S100A12 distinguished active IBD from healthy controls with a sensitivity of 86% and a specificity of 100% </plain></SENT>
<SENT sid="9" pm="."><plain>We also found excellent sensitivity of 86% and specificity of 96% for distinguishing IBD from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IBS</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Faecal S100A12 was also elevated in <z:mp ids='MP_0001794'>bacterial</z:mp> <z:e sem="disease" ids="C0014335" disease_type="Disease or Syndrome" abbrv="">enteritis</z:e> but not in <z:mp ids='MP_0001799'>viral</z:mp> <z:e sem="disease" ids="C0017160" disease_type="Disease or Syndrome" abbrv="">gastroenteritis</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>Faecal S100A12 correlated better with <z:mp ids='MP_0001858'>intestinal inflammation</z:mp> than faecal calprotectin or other biomarkers </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: Faecal S100A12 is a novel non-invasive marker distinguishing IBD from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IBS</z:e> or healthy individuals with a high sensitivity and specificity </plain></SENT>
<SENT sid="13" pm="."><plain>Furthermore, S100A12 reflects inflammatory activity of <z:hpo ids='HP_0011010'>chronic</z:hpo> IBD </plain></SENT>
<SENT sid="14" pm="."><plain>As a marker for neutrophil activation, faecal S100A12 may significantly improve our arsenal of non-invasive biomarkers of <z:mp ids='MP_0001858'>intestinal inflammation</z:mp> </plain></SENT>
</text></document>